Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
We assessed the efficacy of pexacerfont, a CRF1 antagonist, for the treatment of withdrawal symptoms. In this randomized, double-blind, placebo-controlled clinical trial, male patients with amphetamine or opioid dependence, on the basis of the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR), in the age range 18-55 years, received either pexacerfont or placebo (300, 200, and 100 mg/day in the first, second, and third week, respectively). No antidepressants, behavioral interventions, or substitution therapy were administered. Candidates were excluded if they had DSM-IV-TR axis I or II disorders (other than depressive/anxiety disorders). The primary outcomes were difference in the distribution of positive urine test results for heroin and methamphetamine at the end of the trial, and the mean difference in the change in the Visual Analog Scale (VAS) score for craving from the baseline to the endpoint between the two groups. No significant difference was detected for urine test results, but a significant difference was observed for craving scores. Also, significant time×treatment interactions were found for all the scales including VAS craving, VAS temptation severity, frequency of temptation, Clinical Opiate Withdrawal Scale, Amphetamine Withdrawal Questionnaire, Beck Anxiety Inventory, and Beck Depression Inventory II. Our findings favor pexacerfont as a potential treatment for withdrawal from drug dependence; however, further comprehensive studies are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, some preliminary evidence that CRF antagonism may reduce craving for heroin, albeit with no significant reduction in drug use, has been reported (57).”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [57]
Citations
Cites
An inventory for measuring clinical anxiety: Psychometric properties.
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.6.893 · Cited by 14,407
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698
Whiteford, H. A., Ferrari, A. J., Degenhardt, L., Feigin, V., & Vos, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116820 · Cited by 1,175
The Clinical Opiate Withdrawal Scale (COWS)
Wesson, D. R., & Ling, W. (2003) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2003.10400007 · Cited by 1,120
Role of Corticotropin-Releasing Factor in Drug Addiction: Potential for Pharmacological Intervention
Logrip, M. L., Koob, G. F., & Zorrilla, E. P. (2011) · CNS Drugs · doi:10.2165/11587790-000000000-00000 · Cited by 476
Funk, C. K., O'Dell, L. E., Crawford, E. F., & Koob, G. F. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3096-06.2006 · Cited by 381
Funk, C. K., Zorrilla, E. P., Lee, M.-J., Rice, K. C., & Koob, G. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.063 · Cited by 276
The clinical neurobiology of drug craving
Sinha, R. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.05.001 · Cited by 256
Sarnyai, Z., Bíró, É., Gardi, J., Vecsernyés, M., Julesz, J., & Telegdy, G. (1995) · Brain Research · doi:10.1016/0006-8993(95)00043-p · Cited by 255
Research works printed but not linked: 1
- Amiri, 2014, Iran J Psychiatry, 9, 142
Cited by
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice
Kakko, J., Alho, H., Baldacchino, A., Molina, R., Nava, F. A., & Shaya, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00592 · Cited by 140
Ultra-Processed Food Addiction: A Research Update
LaFata, E. M., Allison, K. C., Audrain-McGovern, J. E., & Forman, E. M. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00569-w · Cited by 114
“Interestingly, the medications that led to improvements in UPF addiction have also demonstrated efficacy for decreasing cravings for addictive substances and treating SUDs (though naltrexone and bupropion are prescribed separately for those with an addiction) [72, 73].”
BackgroundJiang, Y., Peng, T., Gaur, U., Silva, M., Little, P. J., Chen, Z., Qiu, W., Zhang, Y., & Zheng, W. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00290 · Cited by 58
Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups
Soares, E. F. P., & Pereira, F. C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1681970 · Cited by 34
“Study design Major findings Year: 2014 [31] Setting: outpatient; two-site Randomization: stratified to balance gender and MA use (1:1) Baseline group differences: n/a METH use (route; frequency; years): n/s; 12/30 d; 12 Treatment: 10 wks + 4 wks (crossover); MPH-SR: 18–54 mg/d, n = 55; PLA: match, n = 55 Visit frequen…”
BackgroundInfluential
Metadata
- Authors
- Morabbi, M.-J., Razaghi, E., Moazen-Zadeh, E., Safi-Aghdam, H., Zarrindast, M. R., Vousoghi, N., & Akhondzadeh, S.
- Affiliations
- Roozbeh Hospital (IR)
- Corresponding author
- Morabbi, Mohammad-Javad
- Razaghi, Emran
- Venue
- International Clinical Psychopharmacology
- Published
- 2018-03
- Volume
- 33
- Issue
- 2
- Pages
- 111-119
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2765215453
- Cited by
- 32
- References
- 29
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 7 · 2023: 1 · 2022: 1 · 2021: 5 · 2020: 8 · 2019: 4 · 2018: 2
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- CRF1 receptor antagonist, heroin addiction, methamphetamine dependence, drug withdrawal symptoms, craving, opioid withdrawal, amphetamine withdrawal, anxiety, depression
- MeSH terms
- CRF Receptor, Type 1, Adult, Central Nervous System Stimulants, Heroin, Double-Blind Method, Humans, Male, Methamphetamine, Middle Aged, Psychiatric Status Rating Scales, Pyrazoles, Severity of Illness Index, Substance Withdrawal Syndrome, Triazines, Substance Abuse Detection, Treatment Outcome, Drug Monitoring, Receptors, Corticotropin-Releasing Hormone, Substance-Related Disorders, Diagnostic and Statistical Manual of Mental Disorders, Visual Analog Scale
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. https://app.cochat.ai/papers/10.1097/yic.0000000000000200
- The paper
- Morabbi, M.-J., Razaghi, E., Moazen-Zadeh, E., Safi-Aghdam, H., Zarrindast, M. R., Vousoghi, N., & Akhondzadeh, S. (2018). Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.